Press Release

Y-mAbs Therapeutics Agrees to Acquisition by SERB Pharmaceuticals

August 5, 2025

New York – August 5, 2025 – Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.

As part of the transaction, SERB will commence an all-cash tender offer to purchase all outstanding shares of Y-mAbs common stock. Holders of Y-mAbs common stock will receive $8.60 per share in cash, representing a premium of approximately 105% to the company’s closing share price on August 4, 2025, the last full trading day prior to the transaction announcement.

Lawyers Bill Sorabella, Bill Roegge, Div Gupta, Sarah Sellers and Ryan Genkin led the Cooley team advising Y-mAbs.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.